Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

GC4419 for Pancreatic Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if GC4419 can prevent some of the side effects of radiation therapy and allow higher doses of radiation to be used.
What is the Condition Being Studied?
Pancreatic Cancer

Who Can Participate in the Study?

Adults who:
-Have pancreatic cancer that cannot be surgically removed

Age Group
Adults

What is Involved?

If you choose to join the study, you will:
-Be randomized (like flipping a coin) into one of two groups:
--Group A will get the study drug (GC4419) and Group B will get a placebo (harmless medicine)
-Have a physical exam
-Have a CT scan
-Complete questionnaires
-Have an endoscopy
-Have a blood draw

Study Details

Full Title
AN ADAPTIVE PHASE I/II DOSE ESCALATION TRIAL OF STEREOTACTIC BODY RADIATION THERAPY IN COMBINATION WITH RADIOMODULATING AGENT GC4419 IN LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA
Principal Investigator
Radiation Oncologist
Protocol Number
IRB: PRO00102370
NCT: NCT03340974
Phase
Phase I/II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698